Ken d’Entremont is the CEO and a Director of Medexus Pharmaceuticals, Inc. He was the founder of Medexus Inc., one of Medexus Pharmaceuticals Inc.'s predecessor companies. Previously, he was the general manager and vice president of business development at Sanofi, where he led the in-licensing initiatives for Sanofi Canada. Mr. d’Entremont holds a Bachelor of Science in Chemistry from McMaster University.

Brendon Buschman joined Medexus in June 2019, most recently serving as VP Finance & Corporate Controller before being appointed Chief Financial Officer in June of 2024. He has over 15 years of experience in accounting, finance and strategy with publicly traded and privately held organizations. Mr. Buschman holds a Master of Finance (MFin) from the Rotman School of Management at the University of Toronto, and a CPA, CA designation.

Ian C Wildgoose Brown has served as Medexus’s general counsel since November 2021. He previously served in senior positions with WeWork and as a corporate associate with Debevoise & Plimpton and WilmerHale. He holds a JD from Harvard Law School, an MSc from the University of Oxford, and a BA from Queen’s University at Kingston and is admitted to practice law in New York.